Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

▤ Summary

Acurx Pharmaceuticals shared new structural biology results from its collaboration with Leiden University Medical Center on DNA pol IIIC inhibitors. The research helps explain how ibezapolstat binds to Gram-positive bacterial targets and supports the company’s antibiotic development strategy. The work also reinforces the rationale for advancing Acurx’s Phase 3 program for C. difficile infection and its broader Gram-positive pipeline. The announcement highlights continued progress in a public-private research partnership, but it does not describe a new product release or corporate transaction.

▦ Linked Companies